No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder

doi:10.1016/j.amepre.2024.05.005

. 2024 Sep;67(3):464-469.

doi: 10.1016/j.amepre.2024.05.005. Epub 2024 May 17.

No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder

Alyssa Tilhou¹, Marielle Baldwin², Justin Alves²

Affiliations

¹ Department of Family Medicine, Boston Medical Center, Boston, Massachusetts. Electronic address: alyssa.tilhou@bmc.org.
² Department of Family Medicine, Boston Medical Center, Boston, Massachusetts.

PMID: 38762205
PMCID: PMC11338722 (available on 2025-09-01)
DOI: 10.1016/j.amepre.2024.05.005

No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder

Alyssa Tilhou et al. Am J Prev Med. 2024 Sep.

. 2024 Sep;67(3):464-469.

doi: 10.1016/j.amepre.2024.05.005. Epub 2024 May 17.

Authors

Alyssa Tilhou¹, Marielle Baldwin², Justin Alves²

Affiliations

¹ Department of Family Medicine, Boston Medical Center, Boston, Massachusetts. Electronic address: alyssa.tilhou@bmc.org.
² Department of Family Medicine, Boston Medical Center, Boston, Massachusetts.

PMID: 38762205
PMCID: PMC11338722 (available on 2025-09-01)
DOI: 10.1016/j.amepre.2024.05.005

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors disclose no conflict of interest.

References

1. Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. Morb Mortal Wkly Rep. 2021;70(6):202. doi:10.15585/mmwr.mm7006a4 - DOI - PMC - PubMed
1. Mojtabai R Estimating the prevalence of substance use disorders in the US using the benchmark multiplier method. JAMA Psychiatry. 2022;79(11):1074–1080. doi:10.1001/jamapsychiatry.2022.2756 - DOI - PMC - PubMed
1. Farrell M, Martin NK, Stockings E, et al. Responding to global stimulant use: challenges and opportunities. The Lancet. 2019;394(10209):1652–1667. doi:10.1016/S0140-6736(19)32230-5 - DOI - PMC - PubMed
1. Sherman JP, Dyar C, Morgan E. Substance use treatment partially mitigates association between methamphetamine use and STI risk: findings from the NSDUH cohort. Sex Transm Infect. 2022;98(3):210–214. doi:10.1136/sextrans-2021-055004 - DOI - PMC - PubMed
1. Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance use by stimulant users: health outcomes over three years. J Stud Alcohol Drugs. 2018;79(5):799–807. doi:10.15288/jsad.2018.79.799 - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

K08 DA058052/DA/NIDA NIH HHS/United States

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

[1] Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. Morb Mortal Wkly Rep. 2021;70(6):202. doi:10.15585/mmwr.mm7006a4 - DOI - PMC - PubMed

[2] Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. Morb Mortal Wkly Rep. 2021;70(6):202. doi:10.15585/mmwr.mm7006a4 - DOI - PMC - PubMed

[3] Mojtabai R Estimating the prevalence of substance use disorders in the US using the benchmark multiplier method. JAMA Psychiatry. 2022;79(11):1074–1080. doi:10.1001/jamapsychiatry.2022.2756 - DOI - PMC - PubMed

[4] Mojtabai R Estimating the prevalence of substance use disorders in the US using the benchmark multiplier method. JAMA Psychiatry. 2022;79(11):1074–1080. doi:10.1001/jamapsychiatry.2022.2756 - DOI - PMC - PubMed

[5] Farrell M, Martin NK, Stockings E, et al. Responding to global stimulant use: challenges and opportunities. The Lancet. 2019;394(10209):1652–1667. doi:10.1016/S0140-6736(19)32230-5 - DOI - PMC - PubMed

[6] Farrell M, Martin NK, Stockings E, et al. Responding to global stimulant use: challenges and opportunities. The Lancet. 2019;394(10209):1652–1667. doi:10.1016/S0140-6736(19)32230-5 - DOI - PMC - PubMed

[7] Sherman JP, Dyar C, Morgan E. Substance use treatment partially mitigates association between methamphetamine use and STI risk: findings from the NSDUH cohort. Sex Transm Infect. 2022;98(3):210–214. doi:10.1136/sextrans-2021-055004 - DOI - PMC - PubMed

[8] Sherman JP, Dyar C, Morgan E. Substance use treatment partially mitigates association between methamphetamine use and STI risk: findings from the NSDUH cohort. Sex Transm Infect. 2022;98(3):210–214. doi:10.1136/sextrans-2021-055004 - DOI - PMC - PubMed

[9] Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance use by stimulant users: health outcomes over three years. J Stud Alcohol Drugs. 2018;79(5):799–807. doi:10.15288/jsad.2018.79.799 - DOI - PMC - PubMed

[10] Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance use by stimulant users: health outcomes over three years. J Stud Alcohol Drugs. 2018;79(5):799–807. doi:10.15288/jsad.2018.79.799 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder

Affiliations

No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder

Authors

Affiliations

Conflict of interest statement

Similar articles

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources